NASDAQ: LTRN - Lantern Pharma Inc.

半年間の収益性: -53.79%
セクタ: Healthcare

プロモーションスケジュール Lantern Pharma Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

さらに詳しく
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

EBITDA -0.0024
Число акций ао 0.01084 млрд
P/BV 6.08
EV/EBITDA 0.5077
Цена ао 10.03
ISIN US51654W1018
Сайт https://www.lanternpharma.com
Валюта usd
IPO date 2020-06-11
Sector Health Care
Industry Biotechnology
Валюта отчета usd
1日あたりの価格変動: -2.96% (3.71)
週ごとの価格変動: -6.25% (3.84)
月ごとの料金変更: -0.277% (3.61)
3ヶ月間の価格変動: -17.81% (4.38)
半年間の価格変動: -53.79% (7.79)
年間の価格変動: +13.56% (3.17)
3年間の価格推移: -69.82% (11.93)
年初からの価格変動: -11.76% (4.08)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 1.08 9
P/E 0 0
EV/EBITDA -1.27 0
合計: 3.63

効率

名前 意味 学年
ROA, % -36.57 0
ROE, % -39.02 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0132 10
合計: 7.8

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 637.61 10
収益性 EPS, % 276.99 10
合計: 8
さらに詳しく

機関 音量 共有, %
Vanguard Group Inc 365334 3.4
NewEdge Advisors, LLC 165972 1.55
Geode Capital Management, LLC 95036 0.88
CM Management, LLC 80000 0.74
Carlson Capital. L.P. 60000 0.56
Commonwealth Equity Services, LLC 58848 0.55
Renaissance Technologies, LLC 43800 0.41
Redmond Asset Management, LLC 40662 0.38
Horizon Kinetics Asset Management LLC 28791 0.27
State Street Corporation 27752 0.26

ETF 共有, % 年間の利益率, % 配当金, %
Dimensional U.S. Core Equity 2 ETF 0.00006 37.528779739064 1.47098
Dimensional U.S. Targeted Value ETF 0.00011 32.980877390326 1.93487
iShares Micro-Cap ETF 0.00743 43.316995205115 1.54048



スーパーバイザー 役職 支払い 生年
Mr. Panna Sharma PH.D. President, CEO & Director 684.38k 1971 (53 年)
Mr. David R. Margrave CFO & Secretary 442.68k 1961 (63 年)
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 283.24k 1955 (69 年)
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor N/A
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations N/A
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics

住所: United States, Dallas. TX, 1920 McKinney Avenue - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.lanternpharma.com